Phase Ib/II Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2032

Conditions

Colorectal Cancer

Interventions

DRUG

Regorafenib

Given Orally

DRUG

Lorigerlimab

Given Orally

Trial Locations (1)

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER